Compare Gilead Sciences, Inc. (GILD) vs Lumen Technologies Inc (LUMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Lumen Technologies Inc — how do they compare? Gilead Sciences, Inc. trades at $135.36 (market cap $163.51B), while Lumen Technologies Inc trades at $6.31 (market cap $6.56B). The key difference: Gilead Sciences, Inc. is far larger — about 24.9× Lumen Technologies Inc's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Lumen Technologies Inc pays none. Which is the better fit depends on your goals.
| GILD | LUMN | |
|---|---|---|
Market Cap | $163.51B | $6.56B |
Sector | Health | Media |
52-Week High | $155.80 | $11.83 |
52-Week Low | $108.22 | $3.70 |
Enterprise Value | $178.05B | $18.19B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
LUMN trades at $6.37, showing no change recently, with a bearish technical signal and mixed earnings history. The company reported a net loss of $1.74B in 2025, though revenue remains substantial at $12.40B. Recent developments include the acquisition of Alkira to enhance AI networking capabilities and cost-cutting initiatives targeting $1B in savings by 2027. Analyst consensus is cautious, with a hold-heavy rating distribution and a $8.25 price target.
The outlook is challenging due to persistent losses and high debt, but strategic acquisitions and efficiency efforts offer potential upside. Risks include execution hurdles and competitive pressures in telecom. Investors should weigh the low P/S ratio against profitability concerns before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Lumen Technologies Inc
With 450,000 route miles of fiber, including over 35,000 route miles of subsea fiber connecting Europe, Asia, and Latin America, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 further shifted the company's operations toward businesses (over 70% of revenue) and away from its legacy consumer business. Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.
Read more on LUMN →
